ClinicalTrials.gg
Sign In

Drug

Donanemab clinical trials

Also written LY3002813 and Kisunla.

studies test it
17
open now
7
in phase 3
7
first study started
2013

Keep track of what changes. Save the donanemab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Donanemab
15

Brand

Kisunla
2

Development codes

LY3002813
12

Studies by the year they started

17 studies that test it; most in 2026 (7)

Studies that test donanemab, by start year
YearStudies
20131
20151
20171
20202
20212
20223
20267

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
5
Phase 3
7
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it.

Alzheimer Disease
13
Down Syndrome
1
Cognitive Dysfunction
1

Who runs them

Industry 14 · Other 3

Eli Lilly and Company (14) · Paul S. Aisen (1) · Michael Rafii, MD, PhD (1) · Banner Health (1)

Often tested with

Tested in the same studies.

AADvac1 (1) · Nivegacetor (1)

Studies

Open first, then newest update. How each study uses donanemab is read from its arms, and is right about nine times in ten.

Testing it · 17

Given in every arm · 1 — donanemab is usual care beside what is tested

Codes

What other systems call donanemab · ClinicalTrials.gg INT002035

  • MeSH (NLM) C000729112donanemabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 1ADB65P1KKDONANEMABConfirmed FDA, NLM
  • NCI Thesaurus C166484DonanemabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.